Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: A case report and literature review

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Ochoa, Roberto ^a   Bejarano, Pablo A ^b   Glück, Stefan ^a   Montero, Alberto J ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; OXYGEN;

AGED; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COUGHING; DRUG INDUCED DISEASE; DYSPNEA; EMERGENCY WARD; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXEMIA; LUNG ALVEOLUS CELL; LUNG ALVEOLUS WALL; LUNG FIBROSIS; LUNG INFILTRATE; MASTECTOMY; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; OXYGEN THERAPY; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84870227594     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-413     Document Type: Review

References (22)

1. Novel cytotoxic drugs: old challenges, new solutions. Ismael GF, Rosa DD, Mano MS, Awada A, Cancer Treat Rev 2008 34 81 91 10.1016/j.ctrv.2007.08.001 17905518
2. Abeloff M, Abeloff's Clinical Oncology Churchill-Livingstone, Philadelphia, Abeloff M, 4 2008 21169260
3. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA, J Clin Oncol 2009 27 1177 1183 10.1200/JCO.2008.18.4028 19204201
4. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M, Anticancer Res 2012 32 1103 1106 22399640
5. Docetaxel-induced fatal interstitial pneumonitis in a patient with castration-resistant prostate cancer. Min BD, Kang HW, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ, Korean J Urol 2012 53 371 374 10.4111/kju.2012.53.5.371 22670199
6. Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L, J Oncol Pharm Pract 2012 18 311 315 10.1177/1078155211429384 22217649
7. Severe interstitial pneumonitis associated with the administration of taxanes. Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y, J Infect Chemother 2010 16 340 344 10.1007/s10156-010-0058-4 20354889
8. Fatal pneumonitis after treatment with docetaxel and trastuzumab. Kuip E, Muller E, Neth J Med 2009 67 237 239 19749395
9. Pneumonitis related to docetaxel: case report and review of the literature. Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW, In Vivo 2009 23 635 637 19567400
10. Acute lung injury associated with docetaxel and bevacizumab. Prat A, Martinez P, Serrano C, Montero MA, Andreu J, Cortes J, Clin Oncol (R Coll Radiol) 2007 19 803 805 10.1016/j.clon.2007.08.010
11. Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Leimgruber K, Negro R, Baier S, Moser B, Resch G, Sansone S, Adami M, Zanon P, Graiff C, Egarter-Vigl E, Wiedermann CJ, Tumori 2006 92 542 544 17260498
12. Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Karacan O, Eyuboglu FO, Akcay S, Ozyilkan O, Onkologie 2004 27 563 565 10.1159/000081339 15591716
13. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V, Lung Cancer 2004 44 363 368 10.1016/j.lungcan.2003.12.004 15140550
14. Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Behrens RJ, Gulley JL, Dahut WL, Am J Ther 2003 10 228 232 10.1097/00045391-200305000-00011 12756431
15. Severe interstitial pneumonitis associated with docetaxel administration. Read WL, Mortimer JE, Picus J, Cancer 2002 94 847 853 10.1002/cncr.10263 11857321
16. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Wang GS, Yang KY, Perng RP, Br J Cancer 2001 85 1247 1250 10.1054/bjoc.2001.2071 11720456
17. Docetaxel and interstitial pulmonary injury. Merad M, Le Cesne A, Baldeyrou P, Mesurolle B, Le Chevalier T, Ann Oncol 1997 8 191 194 10.1023/A:1008226416896 9093730
18. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Mileshkin L, Prince HM, Rischin D, Zimet A, Bone Marrow Transpl 2001 27 559 563 10.1038/sj.bmt.1702803
19. Severe organizing pneumonia after two cycles of docetaxel as fourth-line chemotherapy for advanced non-small cell carcinoma of the lung. Hasskarl J, Schroettner P, von den Berg A, Rueckert A, Frydrychowicz A, Kayser G, Waller CF, Case Rep Oncol 2009 2 12 19 10.1159/000200015 20740139
20. Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma. Cobo Dols M, Gil Calle S, Ales Diaz I, Villar Chamorro E, Alcaide Garcia J, Gutierrez Calderon V, Benavides Orgaz M, Clin Trans Oncol 2006 8 133 135 10.1007/s12094-006-0171-0
21. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Malik SW, Myers JL, DeRemee RA, Specks U, Am J Respir Crit Care Med 1996 154 1851 1856 8970380
22. Ubiquitin-positive pneumocytes and inclusion bodies are present in secondary organizing pneumonia. Yamada T, Sunagawa K, Homma T, Uehara K, Mizutani T, Kawabata Y, Intern Med 2011 50 277 283 10.2169/internalmedicine.50. 4156 21325758